Who we are

Who we are

Neovii is an independent, global biopharmaceutical company with a patient-focused mission to develop and bring to market novel life-transforming therapies to improve the outcomes in transplantation medicine, hemato-oncological and immune disorders.

Neovii was founded following the acquisition of Fresenius Biotech inheriting more than three decades of experience in specialty pharmaceuticals.

What Neovii stands for

Location

Neovii’s global headquarters are located in Rapperswil, Switzerland, and its biologics manufacturing site and German operations are located in Gräfelfing, Germany. Neovii employs approximately 150 employees and has a presence in nearly 60 countries worldwide.

Headquarters

Grafalon history

neovii

1979

ATG-Fresenius® S (now Grafalon®) is manufactured for the first time
neovii

1981

First clinical use in organ transplantation
neovii

1989

First clinical use of the ATG-Fresenius® S polyclonal antibody in stem cell transplantation
neovii

2010

FDA grants orphan drug status and fast track designation for the development of ATG-Fresenius® S for prevention of GVHD in the United States
neovii

2011

German Health Authorities (PEI) approves ATG-Fresenius® S for GVHD prophylaxis in stem cell transplantation in Germany
neovii

2013

Fresenius Biotech becomes Neovii
neovii

2014

Neovii global headquarters are established in Rapperswil, Switzerland
neovii

2015

ATG-Fresenius® S is re-branded and launched as GRAFALON®.

Mission

We are dedicated to bringing life-transforming therapies to patients with unmet needs around the world. 

Neovii mission
Neovii mission

Our vision

Neovii aspires to be a fully integrated global pharmaceutical company with several franchises focused on diseases with unmet needs. We continually support customers up and down the value chain and are always in pursuit of maximizing total patient care.

We believe that our competencies and strengths combined with our values and culture make Neovii an employer of choice.